Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Incidentally discovered sellar masses (pituitary incidentalomas)

Peter J Snyder, MD
Section Editor
David S Cooper, MD
Deputy Editor
Kathryn A Martin, MD


The frequent detection of unsuspected anatomic abnormalities in many glands ("incidentalomas"), including the pituitary, made possible by the sensitivity of magnetic resonance imaging (MRI), raises the question of how to evaluate patients who have such an abnormality. The causes, evaluation, and treatment of pituitary incidentaloma are discussed here. The causes, clinical presentation, and evaluation of sellar masses are reviewed separately. (See "Causes, presentation, and evaluation of sellar masses".)


The term “pituitary incidentaloma” refers to a previously unsuspected lesion that is detected on an imaging study performed for reasons other than pituitary symptoms or disease. Among adults undergoing imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) for reasons other than pituitary symptoms or disease, the frequency of incidentally discovered signal abnormalities (<10 mm) varies among studies from 4 to 20 percent by CT [1-3] and 10 to 38 percent by MRI [4,5].

Not all incidentally discovered sellar masses are pituitary adenomas. In one study of 61 incidentally discovered sellar masses found among 1000 unselected autopsy specimens, there were 37 Rathke’s cleft cysts, 18 pituitary adenomas, and two each of hyperplasia, infarction, and hemorrhage [6]. However, pituitary adenomas are a common finding, as illustrated by a review of 29 autopsy studies that included over 18,000 pituitary glands [7]. The frequency of pituitary adenomas was approximately 10 percent, and nearly all of the adenomas were microadenomas (<10 mm). The frequencies were similar for men and women, and across age groups in adults.


Patients who are referred for evaluation of incidentally discovered magnetic resonance imaging (MRI) signal abnormalities within the sella tend to have larger lesions and a higher incidence of neurologic abnormalities than would be expected from autopsy and MRI series of unselected patients [8,9]. This presumably reflects the selection process of a referral population. In one series of 31 referred patients, 16 had lesions 10 mm or larger [9]. Three of the 31 patients had hormonal abnormalities; two had slightly high serum alpha-subunit concentrations, and two mild hyperprolactinemia (one patient had both). In the largest reported series of incidentally discovered sellar masses, 506 patients were reported from referral centers, in response to a questionnaire, to have incidentally-discovered sellar masses; the majority were >10 mm [10].

The overall frequency of different types of pituitary adenomas is not known because many large series of incidentally discovered sellar masses intentionally exclude those patients who have lesions that are hypersecreting. In our experience, however, it is common for a sellar mass that is discovered incidentally to be associated, on further evaluation, with obvious clinical consequences, including visual impairment and hormonal hypersecretion. Some of these patients even have obvious clinical manifestations of the hypersecretion (eg, acromegaly) that had been overlooked until the mass was discovered.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: May 7, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Peyster RG, Adler LP, Viscarello RR, et al. CT of the normal pituitary gland. Neuroradiology 1986; 28:161.
  2. Wolpert SM, Molitch ME, Goldman JA, Wood JB. Size, shape, and appearance of the normal female pituitary gland. AJR Am J Roentgenol 1984; 143:377.
  3. Chambers EF, Turski PA, LaMasters D, Newton TH. Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes. Radiology 1982; 144:109.
  4. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817.
  5. Chong BW, Kucharczyk W, Singer W, George S. Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 1994; 15:675.
  6. Teramoto A, Hirakawa K, Sanno N, Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994; 193:161.
  7. Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37:151.
  8. Reincke M, Allolio B, Saeger W, et al. The 'incidentaloma' of the pituitary gland. Is neurosurgery required? JAMA 1990; 263:2772.
  9. Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995; 155:181.
  10. Sanno N, Oyama K, Tahara S, et al. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol 2003; 149:123.
  11. Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf) 2007; 67:938.
  12. Fernández-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96:905.
  13. Wade AN, Baccon J, Grady MS, et al. Clinically silent somatotroph adenomas are common. Eur J Endocrinol 2011; 165:39.
  14. Karavitaki N, Ansorge O, Wass JA. Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 2007; 51:1314.
  15. Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol 2007; 156:217.
  16. King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab 1997; 82:3625.
  17. Freda PU, Beckers AM, Katznelson L, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:894.